Rademikibart produced rapid, placebo‑corrected lung function gains in a small IV study—FEV1 improvements were seen within 15 minutes, stabilized at ~200–300 mL in asthma and ~300–400 mL in COPD, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results